LTRN · XBRL financial data

Lantern Pharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LTRN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	2,210	3,573*	4,251	3,889	3,717	4,270*	3,264	3,068	2,437	2,745*	1,725	1,791
General and administrative	1,314	1,304*	1,481	1,520	1,463	1,627*	1,510	1,584	1,913	1,458*	1,680	1,717
Total operating expenses	3,524	4,877*	5,732	5,408	5,180	5,896*	4,774	4,652	4,350	4,203*	3,405	3,508
Operating income (loss)	(3,524)	(4,877)*	(5,732)	(5,408)	(5,180)	(5,896)*	(4,774)	(4,652)	(4,350)	(4,203)*	(3,405)	(3,508)
Other income (expense)	116	424*	90	260	483	(140)*	87	206	71	56*	34	15
Net income (loss)	(3,161)	(4,186)*	(5,441)	(4,960)	(4,506)	(5,875)*	(4,537)	(4,331)	(4,177)	(4,074)*	(3,329)	(7,072)
Earnings per share, basic USD per share	(0.29)	(0.39)*	(0.51)	(0.46)	(0.42)	(0.54)*	(0.42)	(0.40)	(0.39)	(0.36)*	(0.30)	(0.57)
Earnings per share, diluted USD per share	(0.29)	(0.39)*	(0.51)	(0.46)	(0.42)	(0.54)*	(0.42)	(0.40)	(0.39)	(0.36)*	(0.30)	(0.57)
Weighted average shares, basic thousands of shares	10,857	10,798*	10,743	10,759	10,763	10,784*	10,785	10,785	10,833	11,186*	11,253	12,423
Weighted average shares, diluted thousands of shares	10,857	10,798*	10,743	10,759	10,763	10,784*	10,785	10,785	10,833	11,186*	11,253	12,423

Fiscal quarters (LTRN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	25,572	21,938	18,358	12,977	8,103	7,511	6,378	6,061	8,389	4,423	4,918	6,660
Marketable securities	19,354	19,365	20,000	20,286	19,951	16,502	13,344	9,840	3,973	5,696	1,405	701
Prepaid and other current assets	2,500	2,039	1,113	2,029	1,867	1,235	1,102	1,299	1,098	684	734	1,098
Total current assets	47,426	43,341	39,471	35,292	29,921	25,248	20,823	17,201	13,461	10,803	7,057	8,459
Property and equipment, net	51	52	50	50	49	47	44	40	36	32	28	24
Right-of-use asset	269	228	187	213	287	240	192	143	93	76	57	38
Total assets	47,772	43,648	39,734	35,587	30,293	25,572	21,096	17,420	13,627	11,036	7,223	8,602
Total current liabilities	2,253	2,678	3,953	4,601	3,601	4,331	4,286	4,884	4,040	4,502	3,777	4,323
Lease liability, non-current	107	61	16	55	94	53	33	14	—	—	—	—
Total liabilities	2,360	2,740	3,969	4,655	3,695	4,384	4,320	4,898	4,040	4,502	3,777	11,820
Accumulated deficit	(51,058)	(55,244)	(60,685)	(65,645)	(70,150)	(76,026)	(80,562)	(84,893)	(89,071)	(93,145)	(96,474)	(103,546)
Total stockholders' equity	45,412	40,908	35,765	30,931	26,598	21,188	16,776	12,522	9,587	6,534	3,446	(3,217)
Total liabilities and equity	47,772	43,648	39,734	35,587	30,293	25,572	21,096	17,420	13,627	11,036	7,223	8,602
Common shares outstanding (cover page) thousands of shares	10,869	10,741	10,759	10,765	10,785	10,785	10,785	10,799	11,184	11,255	11,305	12,784

Fiscal quarters (LTRN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,161)	(4,186)*	(5,441)	(4,960)	(4,506)	(5,875)*	(4,537)	(4,331)	(4,177)	(4,074)*	(3,329)	(7,072)
Stock-based compensation	191	151*	134	134	179	205*	148	161	144	199*	—	—
Depreciation and amortization	4*	4*	4	4*	—	—	—	—	—	—	—	—
Net cash from operating activities	(3,612)*	(3,385)*	(3,069)	(5,191)*	(5,582)*	(3,972)*	(4,376)	(3,937)*	(4,572)*	(2,792)*	(3,773)	(2,941)*
Purchases of property and equipment	5*	5*	2	4*	3*	3*	1	0*	1*	0*	—	—
Net cash from investing activities	232*	256*	(556)	(202)*	680*	3,447*	3,239	3,593*	5,929*	(1,704)*	4,250	692*
Proceeds from issuing common stock	—	—	—	—	—	—	—	—	31	666*	—	—
Share repurchases	—	year only	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	—	year only	55	0*	12*	0*	—	—	—	526*	—	—
Net change in cash	(3,393)*	(3,634)*	(3,580)	(5,381)*	(4,874)*	(592)*	(1,133)	(316)*	2,328*	(3,967)*	495	1,742*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lantern Pharma	6,660	not reported	(2,941)*	12.8M	2.5 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Annovis Bio	18,729	0*	(21,914)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	54,980	33,432	(24,931)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.